Sérgio Lago
Hospital São Lucas da PUCRS · 17 works · 354 citations · h-index 4
Top works
- Symptom Improvement in Lung Cancer Patients Treated With Erlotinib: Quality of Life Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
- SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer
- PCN33 COST-MINIMIZATION ANALYSIS OF ONCE-PER-CYCLE FIXED-DOSE ADMINISTRATION OF PEGFILGRASTIM VERSUS DAILY FILGRASTIM FORTHE PROPHYLAXIS OF CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA IN BRAZIL
- 446 Quality of life (QoL) in patients with metastatic breast cancer (MBC) treated with capecitabine (Xeloda)
- Effects of capecitabine (X) on quality of life (QoL) in patients (pts) with metastatic colorectal cancer (MCRC)
- Phase II multicenter trial of docetaxel, epirubicin, and 5-fluorouracil (DEF) in the treatment of advanced gastric cancer: a novel, safe, and active regimen
- Effect of capecitabine (X) on quality of life (QoL) in patients (pts) with metastatic breast cancer (MBC)
- 370 Primary treatment with weekly docetaxel (Taxotere) and trastuzumab (Herceptin) for HER-2 overexpressing locally advanced breast cancer
- Effect of crossover from placebo to darolutamide on overall survival in men with non-metastatic prostate cancer: sensitivity analyses from the randomised phase 3 ARAMIS study
- Analysis of the effect of crossover from placebo (PBO) to darolutamide (DARO) on overall survival (OS) benefit in the ARAMIS Trial.
- Quimioterapia Adjuvante no Câncer da Mama
- Doença de Hodgkin: Estudo Epidemiológico e Clinico em uma População Parcial no Rio Grande do Sul
- 300 Effects of capecitabine (Xeloda) on quality of life (QoL) in patients with metastatic colorectal cancer (MCRC)
- Nefrotoxicidade da Cisplatina
- Quality of life (QoL) improvements in patients (pts) with metastatic breast cancer (MBC) receiving capecitabine (X)
- Improvement in quality of life (QoL) and ECOG in a cohort of 1125 patients (pts) with metastatic breast cancer (MBC) treated with capecitabine (X)
- Identificação do linfonodo-sentinela: uso de novos marcadores